Jubilant Life Sciences (JLS) delivered higher-than-expected 3QFY21 earnings, led by better traction in a) the Contract Manufacturing Organization (CMO) / Generics category of the Pharma segment and b) Nutritional products in the Life Science Ingredient (LSI) business. Post the demerger of LSI with Jubilant Ingrevia from 1st Feb'21, the segment is classified as discontinued operations'; JLS has been renamed Jubilant Pharmova (JP), which would now comprise the Specialty Pharma, CMO, Generics, Contract Research and Development, and Drug Discovery businesses....